Imugex

Shipping cost plus VAT not included , delivery in 7-14 business days

Categories: Diagnostics / Diagnostics

Product name			MDS chromosome and gene anomaly detection probe, D7S522/CEP7 (CE-IVD)
Catalog No			FP-011-2
Supplier’s Catalog No			FP-011-2
Supplier			Wuhan Healthcare Biotech
Source antigen			MDS
Reactivity			MDS
Cross reactivity			None
Applications			Fluorescence In Situ Hybridization (FISH)
Molecular weight			N/A

Storage			-20°C
Other names
Grade			Molecular diagnostic grade
Purity			N/A
Form			Liquid
Reactivity life			12 months when stored properly according to instructions
Note			For Professional In Vitro diagnostics
Description			Among the common chromosomal abnormalities in MDS patients, some chromosomal abnormalities have specific diagnostic value. Some patients with simple +8, 20q- or Y- are effective in immunosuppressive therapy, karyotyping is also of great value in the classification, treatment and prognosis of MDS, such as single Y-, 5q- or 20q-MDS Patients had a better prognosis, and patients with complex chromosomal abnormalities (≥3 abnormalities) or chromosome 7 abnormalities had a poor prognosis, and other abnormal patients had a moderate prognosis. NCCN and the “Chinese Expert Consensus for the Diagnosis and Treatment of Myelodysplastic Syndrome (2014 Edition)” recommend that all patients suspected of having MDS should have a chromosomal test, and fluorescent in situ hybridization probes (commonly abnormal sets of probes) are recommended. Abnormalities are important for the diagnosis, treatment, and prognosis of MDS.